Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.58 |
| ▸ | FNTA | P49354 | 2/20 | 0.58 |
| ▸ | FNTB | P49356 | 2/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neryl Acetate SCHEMBL236190 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| Geranyl Acetate SCHEMBL56913 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| Neryl Acetate SCHEMBL1865830 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| Geranyl Acetate SCHEMBL56914 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| Geranyl Acetate SCHEMBL1869319 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL11404530 | 0.98 | ALDH1A1 (0.96) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL1301765 | 0.98 | ALDH1A1 (0.96) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL133908 | 0.98 | ALDH1A1 (0.96) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL11410939 | 0.98 | ALDH1A1 (0.96) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| Geranyl Acetate SCHEMBL21436816 | 0.98 | ALDH1A1 (0.96) | ALDH1A1ALOX15TRPV1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11062794-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-07-13 | — | — | US | disclosed |
| US-20190321306-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | CMG PARTNERS INC (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190275268-A1 | MULTI-USE CARTRIDGE FOR INGESTION OF CANNABIS-BASED PRODUCTS | CMG PARTNERS INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190224142-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | CMG PARTNERS INC (US) | 2019-07-25 | — | — | US | disclosed |
| US-20190175523-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | CMG PARTNERS INC (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190134125-A1 | ENHANCED SMOKABLE THERAPEUTIC CANNABIS PRODUCT AND METHOD FOR MAKING SAME | CMG PARTNERS INC (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3465198-A1 | METHOD OF RESOLVING ALLERGENS IN PERFUME INGREDIENTS | Givaudan S.A. (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10206888-B2 | Cannabis-based therapeutic product for treatment of chronic pain | CMG PARTNERS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180352848-A1 | SMOKABLE CANNABIS-BASED PRODUCT WITH REDUCED PSYCHOACTIVE EFFECTS | CMG PARTNERS, INC. | 2018-12-13 | — | — | US | disclosed |
| US-20180344684-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF SLEEP DISORDERS | CMG PARTNERS, INC. | 2018-12-06 | — | — | US | disclosed |
| WO-2013035070-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-03-14 | — | — | WO | disclosed |
| EP-2496682-A1 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011075556-A1 | COMPOSITION COMPRISING ENCAPSULATES, AND PROCESS FOR MAKING THEM | THE PROCTER & GAMBLE COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075551-A1 | PERFUMES AND PERFUME ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011056934-A1 | HIGH EFFICIENCY CAPSULES COMPRISING BENEFIT AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056935-A1 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010117740-A2 | ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROL | TYRATECH, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115065-A2 | METHODS FOR PEST CONTROL EMPLOYING MICROEMULSION-BASED ENHANCED PEST CONTROL FORMULATIONS | TYRATECH, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2009117621-A1 | PEST CONTROL COMPOSITIONS AND METHODS | TYRATECH, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206888-B2 | Cannabis-based therapeutic product for treatment of chronic pain | CNR2, CNR1, HHAT | ALDH1A1 4661/4885ALOX15 144/4885TRPV1 37/4885 |
| US-20190175523-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | CNR2, CNR1, MCCC2 | ALDH1A1 4620/4885ALOX15 242/4885TRPV1 40/4885 |
| US-20190134125-A1 | ENHANCED SMOKABLE THERAPEUTIC CANNABIS PRODUCT AND METHOD FOR MAKING SAME | CNR2, CNR1, GPR18 | ALDH1A1 4591/4885ALOX15 957/4885TRPV1 185/4885 |
| US-20190321306-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | CNR2, CNR1, MCCC2 | ALDH1A1 4724/4885ALOX15 287/4885TRPV1 22/4885 |
| US-20180344684-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF SLEEP DISORDERS | CNR2, CNR1, FAAH | ALDH1A1 3900/4885ALOX15 47/4885TRPV1 640/4885 |
| US-20190224142-A1 | CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN | CNR2, CNR1, MCCC2 | ALDH1A1 4724/4885ALOX15 287/4885TRPV1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.